Global elimination of mother-to-child transmission of hepatitis B: Revisiting the current strategy

The Lancet Infectious Diseases

Volumn 15, Issue 8, 2015, Pages 981-985

  Thio, Chloe L ^a,b   Guo, Nan ^b   Xie, Chan ^c   Nelson, Kenrad E ^a,b   Ehrhardt, Stephan ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; VIRUS DNA; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

COST EFFECTIVENESS ANALYSIS; HEPATITIS B; HUMAN; IMMUNOPROPHYLAXIS; LOWEST INCOME GROUP; NOTE; PRIORITY JOURNAL; SEROPREVALENCE; VACCINATION; VERTICAL TRANSMISSION; VIRUS TRANSMISSION; FEMALE; HEPATITIS B VIRUS; IMMUNOLOGY; MOTHER; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREVENTION AND CONTROL; VIROLOGY;

FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; MOTHERS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84937734756     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00158-9     Document Type: Note

References (42)

1. Global immunization data WHO, (accessed April 1, 2014). http://www.who.int/immunization/monitoring_surveillance/Global_Immunization_Data.pdf.
2. Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol 2012, 4:74-80.
3. Xu Y, Liu H, Wang Y, Hao R, Li Z, Song H The next step in controlling HBV in China. BMJ 2013, 347:f4503.
4. Kiire CF The epidemiology and prophylaxis of hepatitis B in sub-Saharan Africa: a view from tropical and subtropical Africa. Gut 1996, 38(38):S5-S12.
5. Hepatitis B vaccines. Wkly Epidemiol Rec 2009, 84:405-419. WHO.
6. Peng CY, Chien RN, Liaw YF Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012, 57:442-450.
7. Patel MK, Capeding RZ, Ducusin JU, de Quiroz Castro M, Garcia LC, Hennessey K Findings from a hepatitis B birth dose assessment in health facilities in the Philippines: opportunities to engage the private sector. Vaccine 2014, 32:5140-5144.
8. Temperature sensitivity of vaccines. WHO/IVB/06.10 2006, WHO, World Health Organization, Geneva.
9. Petersen J HBV treatment and pregnancy. J Hepatol 2011, 55:1171-1173.
10. Global routine vaccination coverage-2012. MMWR Morb Mortal Wkly Rep 2013, 62:858-861. Centers for Disease Control and Prevention (CDC).
11. Hu Y, Zhang S, Luo C, Liu Q, Zhou YH Gaps in the prevention of perinatal transmission of hepatitis B virus between recommendations and routine practices in a highly endemic region: a provincial population-based study in China. BMC Infect Dis 2012, 12:221.
12. Huang Y, Li L, Sun X, et al. Screening of pregnant women for hepatitis B virus surface antigen (HBsAg) and subsequent management, Qiandongnan prefecture, Guizhou, China, 2010. Vaccine 2013, 31(31):S62-S65.
13. Hepatitis B vaccine birthdose practices in a country where hepatitis B is endemic-Laos, December 2011-February 2012. MMWR Morb Mortal Wkly Rep 2013, 62:587-590. Centers for Disease Control and Prevention (CDC).
14. Wang L, Li J, Chen H, et al. Hepatitis B vaccination of newborn infants in rural China: evaluation of a village-based, out-of-cold-chain delivery strategy. Bull World Health Organ 2007, 85:688-694.
15. Patton H, Tran TT Management of hepatitis B during pregnancy. Nat Rev Gastroenterol Hepatol 2014, 11:402-409.
16. Pan CQ, Duan ZP, Bhamidimarri KR, et al. An algorithm for risk assessment and intervention of mother to child transmission of hepatitis B virus. Clin Gastroenterol Hepatol 2012, 10:452-459.
17. Bleich LM, Swenson ES Prevention of neonatal hepatitis B virus transmission. J Clin Gastroenterol 2014, 48:765-772.
18. Ott JJ, Stevens GA, Wiersma ST The risk of perinatal hepatitis B virus transmission: hepatitis B e antigen (HBeAg) prevalence estimates for all world regions. BMC Infect Dis 2012, 12:131.
19. Celen MK, Mert D, Ay M, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy for the prevention of vertical transmission of HBV infection. World J Gastroenterol 2013, 19:9377-9382.
20. Xu WM, Cui YT, Wang L, et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. J Viral Hepat 2009, 16:94-103.
21. Han GR, Cao MK, Zhao W, et al. A prospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. J Hepatol 2011, 55:1215-1221.
22. Greenup A-J, Tan PK, Nguyen V, et al. Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus. J Hepatol 2014, 61:502-507.
23. Shivkumar S, Peeling R, Jafari Y, Joseph L, Pai NP Rapid point-of-care first-line screening tests for hepatitis B infection: a meta-analysis of diagnostic accuracy (1980-2010). Am J Gastroenterol 2012, 107:1306-1313.
24. Werayingyong P, Phanuphak N, Chokephaibulkit K, et al. Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand. Asia Pac J Public Health 2013, published online June 11. 10.1177/1010539513489134.
25. Govender T, Coovadia H Eliminating mother to child transmission of HIV-1 and keeping mothers alive: recent progress. J Infect 2014, 68(68):S57-S62.
26. Department of AIDS control, annual report 2013-14 Government of India, (accessed Oct 26, 2014). http://www.naco.gov.in/upload/2014%20mslns/NACO_English%202013-14.pdf.
27. Burk RD, Hwang LY, Ho GY, Shafritz DA, Beasley RP Outcome of perinatal hepatitis B virus exposure is dependent on maternal virus load. J Infect Dis 1994, 170:1418-1423.
28. Söderström A, Norkrans G, Lindh M Hepatitis B virus DNA during pregnancy and post partum: aspects on vertical transmission. Scand J Infect Dis 2003, 35:814-819.
29. Ehrhardt S, Xie C, Guo N, Nelson K, Thio CL Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: a review of the evidence. Clin Infect Dis 2015, 60:275-278.
30. Wiens A, Lenzi L, Venson R, et al. Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B: a mixed-treatment comparison meta-analysis. Pharmacotherapy 2013, 33:144-151.
31. Sax P, Brar I, Elion R, et a. 48-week study of tenofovir alafenamide (TAF) versus tenofovir disoproxil fumarate (TDF), each in a single tablet regimen (STR) with elvitegravir, cobicistat, and emtricitabine [E/C/F/TAF vs. E/C/F/TDF] for initial HIV treatment. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013), Denver, CO, USA; Sept 10-13, 2013. Abstract H1464d.
32. Liu Y, Kitrinos K, Babusis D, et al. Lack of tenofovir alafenamide (TAF) effect on primary osteoblasts in vitro at clinically relevant drug concentrations. Abstract H-664. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). Denver, CO, USA; Sept 10-13, 2013. Abstr H-664.
33. Ayres A, Yuen L, Jackson KM, et al. Short duration of lamivudine for the prevention of hepatitis B virus transmission in pregnancy: lack of potency and selection of resistance mutations. J Viral Hepat 2014, 21:809-817.
34. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization?. Bull World Health Organ 2010, 88:66-73.
35. Corsa AC, Liu Y, Flaherty JF, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol 2014, 12:2106-2112. e1.
36. Lai CL, Gane E, Liaw YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007, 357:2576-2588. the Globe Study Group.
37. Viganò A, Mora S, Giacomet V, et al. In utero exposure to tenofovir disoproxil fumarate does not impair growth and bone health in HIV-uninfected children born to HIV-infected mothers. Antivir Ther 2011, 16:1259-1266.
38. Gibb DM, Kizito H, Russell EC, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med 2012, 9:e1001217. the DART trial team.
39. Siberry G, Jacobson D, Kalkwarf H, et al. Lower newborn bone mineral content associated with maternal use of tenofovir disoproxil fumarate. 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014). Boston, MA, USA; March 3-6, 2014. Abstract 71.
40. Kourtis AP, Bulterys M, Hu DJ, Jamieson DJ HIV-HBV coinfection-a global challenge. N Engl J Med 2012, 366:1749-1752.
41. Barron P, Pillay Y, Doherty T, et al. Eliminating mother-to-child HIV transmission in South Africa. Bull World Health Organ 2013, 91:70-74.
42. World AIDS day report 2012 UNAIDS, (accessed May 13, 2014). http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/jc2434_worldaidsday_results_en.pdf.